title: Polymorphisms of xenobiotic metabolizing enzymes and DNA repair genes and outcome in childhood acute lymphoblastic leukemia.
abstract: The interindividual variation in the activity of xenobiotic metabolizing enzymes and DNA repair genes could modify an individual's risk of recurrent malignancy and response to therapy. We investigated whether ALL outcome was related to polymorphisms in genes CYP2D6, MPO, EPHX1, NQO1, TS, XPD and XRCC1 in 95 consecutive ALL children by PCR or PCR-FRLP techniques. Polymorphisms in genes NQO1 and TS were associated with a significantly slow response to induction chemotherapy and NQO1 was also associated with a lower five-year event-free survival. This study suggests that polymorphisms of NQO1 and TS could be important for patient response to induction therapy and for treatment outcome.
authors.affiliation: Department of Genetics, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.
authors.forename: Vanessa
authors.initials: V
authors.lastname: da Silva Silveira
authors.forename: Renata
authors.initials: R
authors.lastname: Canalle
authors.forename: Carlos Alberto
authors.initials: CA
authors.lastname: Scrideli
authors.forename: Rosane Gomes de Paula
authors.initials: RG
authors.lastname: Queiroz
authors.forename: Heloisa
authors.initials: H
authors.lastname: Bettiol
authors.forename: Elvis Terci
authors.initials: ET
authors.lastname: Valera
authors.forename: Luiz Gonzaga
authors.initials: LG
authors.lastname: Tone
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics; D004260:DNA Repair; D045643:DNA Repair Enzymes / Q000235:genetics*; D004268:DNA-Binding Proteins / Q000235:genetics; D004851:Epoxide Hydrolases / Q000235:genetics; D005260:Female; D005434:Flow Cytometry; D016179:Granulocyte Colony-Stimulating Factor / Q000235:genetics; D006801:Humans; D007377:Interleukin-3 / Q000235:genetics; D008297:Male; D016660:NAD(P)H Dehydrogenase (Quinone) / Q000235:genetics; D011110:Polymorphism, Genetic / Q000235:genetics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D011379:Prognosis; D011993:Recombinant Fusion Proteins / Q000235:genetics; D011994:Recombinant Proteins; D012074:Remission Induction; D015996:Survival Rate; D013940:Thymidylate Synthase / Q000235:genetics; D016896:Treatment Outcome; D000076105:X-ray Repair Cross Complementing Protein 1; D051759:Xeroderma Pigmentosum Group D Protein / Q000235:genetics
chemical_list: D004268:DNA-Binding Proteins; D007377:Interleukin-3; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins; D000076105:X-ray Repair Cross Complementing Protein 1; C000619371:XRCC1 protein, human; C404145:myelopoietin; D016179:Granulocyte Colony-Stimulating Factor; D019389:Cytochrome P-450 CYP2D6; D016660:NAD(P)H Dehydrogenase (Quinone); C447479:NQO1 protein, human; D013940:Thymidylate Synthase; D004851:Epoxide Hydrolases; C522330:EPHX1 protein, human; D051759:Xeroderma Pigmentosum Group D Protein; C497292:ERCC2 protein, human; D045643:DNA Repair Enzymes